Active Ingredient: Nivolumab
Nivolumab in combination with cabozantinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma.
For this indication, competent medicine agencies globally authorize below treatments:
For:
Regimen A: Intravenous, 240 milligrams nivolumab, once every 2 weeks.
Regimen B: Intravenous, 480 milligrams nivolumab, once every 4 weeks.
The recommended dose is nivolumab administered intravenously at either 240 mg every 2 weeks or 480 mg every 4 weeks in combination with 40 mg cabozantinib administered orally every day.
Recommended doses and infusion times for intravenous administration of nivolumab in combination with oral administration of cabozantinib for RCC:
| Combination phase | |
|---|---|
| Nivolumab | 240 mg every 2 weeks over 30 minutes or 480 mg every 4 weeks over 60 minutes |
| Cabozantinib | 40 mg once daily |
Nivolumab must not be administered as an intravenous push or bolus injection.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.
